{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:15:33Z","timestamp":1787015733534,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":2593,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Novo Nordisk Health Care"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1111\/jth.13134","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T11:25:17Z","timestamp":1441365917000},"page":"2041-2052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive"],"prefix":"10.1016","volume":"13","author":[{"given":"E.K.","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ezban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13134_bb0010","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2141.2011.08765.x","article-title":"Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements","volume":"154","author":"Skinner","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13134_bb0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13134_bb0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH12-02-0108","article-title":"Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A","volume":"109","author":"Gomez","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2516.2006.01330.x","article-title":"Factor VIII and thrombin generation assays: relevance to pharmacokinetic studies in haemophilia A","volume":"12","author":"Barrowcliffe","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13134_bb0030","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 4","key":"10.1111\/jth.13134_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/hae.12428","article-title":"Novel products for haemostasis \u2013 current status","volume":"20","author":"Oldenburg","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13134_bb0040","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first\u2010in\u2010human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2516.2009.02135.x","article-title":"Purification and characterization of a new recombinant factor VIII (N8)","volume":"16","author":"Thim","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13134_bb0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2516.2012.02896.x","article-title":"Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8\u2010GP in haemophilia A dogs","volume":"18","author":"Agerso","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13134_bb0055","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2516.2011.02495.x","article-title":"Bioequivalence between two serum\u2010free recombinant factor VIII preparations (N8 and ADVATE(R)) \u2013 an open\u2010label, sequential dosing pharmacokinetic study in patients with severe haemophilia A","volume":"17","author":"Martinowitz","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13134_bb0060","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jth.12000","article-title":"Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9\u2010GP), a glycoPEGylated recombinant factor IX","volume":"10","author":"Collins","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0065","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half\u2010life and preserved enzymatic properties of factor IX selectively PEGylated on native N\u2010glycans in the activation peptide","volume":"118","author":"Ostergaard","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.13134_bb0070","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long\u2010acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.13134_bb0075","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/hae.12374","article-title":"Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94\u20109027) for haemophilia A","volume":"20","author":"Gu","year":"2014","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1111\/jth.13134_bb0080","first-page":"970","article-title":"Influence of FIX and FVIII PEGylation on FIX and FVIII activity based on APTT assays","volume":"11","author":"Lochu","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0085","first-page":"45","article-title":"PEGylation of FIX influences the clotting time in APTT assays. Use of product specific standard eliminates PEG interference","volume":"19","author":"Hermit","year":"2013","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1111\/jth.13134_bb0090","first-page":"828","article-title":"The activity of GlycoPEGylated recombinant FIX (N9\u2010GP) can be measured in two\u2010stage chromogenic and one\u2010stage clotting assays","volume":"11","author":"Holm","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MBC.0000000000000176","article-title":"Artifactual prolongation of activated partial thromboplastin time with PEGylated compounds in silica\u2010based assays","volume":"25","author":"Murphy","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13134_bb0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper\u2010 and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.13134_bb0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.thromres.2012.07.017","article-title":"Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study","volume":"130","author":"Dargaud","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13134_bb0110","first-page":"WMC001116","article-title":"Modified thrombin generation assay: application to the analysis of immunoglobulin concentrates","volume":"1","author":"Grundmann","year":"2010","journal-title":"WebMedCentral Immunotherapy"},{"key":"10.1111\/jth.13134_bb0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jth.12452","article-title":"Measurement of factor IX activity in plasma\u2010derived and recombinant concentrates: insights from thrombin generation and activation\u2010based assays","volume":"12","author":"Yu","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0120","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti\u2010factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13134_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.13134_bb0130","doi-asserted-by":"crossref","DOI":"10.1111\/hae.12680","article-title":"Factor IX\u2010deficient plasma spiked with N9\u2010GP behaves similarly to N9\u2010GP post\u2010administration clinical samples in N9\u2010GP ELISA and FIX activity assays","author":"S\u00f8rensen","year":"2015","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13134","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622086925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622086925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13134\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:10:39Z","timestamp":1761534639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622086925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1538783622086925"],"URL":"https:\/\/doi.org\/10.1111\/jth.13134","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}